Metabolic modulation with perhexiline in chronic heart failure - a randomized, controlled trial of short-term use of a novel treatment

Simple item page
dc.contributor.authorLee, L.
dc.contributor.authorCampbell, R.
dc.contributor.authorScheuermann-Freestone, M.
dc.contributor.authorTaylor, R.
dc.contributor.authorGunaruwan, P.
dc.contributor.authorWilliams, L.
dc.contributor.authorAshrafian, H.
dc.contributor.authorHorowitz, J.
dc.contributor.authorFraser, A.
dc.contributor.authorClarke, K.
dc.contributor.authorFrenneaux, M.
dc.date.issued2005
dc.descriptionCopyright © 2007 Lippincott Williams & Wilkins
dc.description.abstract<h4>Background</h4>Chronic heart failure (CHF) is a major cause of morbidity and mortality that requires a novel approach to therapy. Perhexiline is an antianginal drug that augments glucose metabolism by blocking muscle mitochondrial free fatty acid uptake, thereby increasing metabolic efficiency. We assessed the effects of perhexiline treatment in CHF patients.<h4>Methods and results</h4>In a double-blind fashion, we randomly assigned patients with optimally medicated CHF to either perhexiline (n=28) or placebo (n=28). The primary end point was peak exercise oxygen consumption (VO2max), an important prognostic marker. In addition, the effect of perhexiline on myocardial function and quality of life was assessed. Quantitative stress echocardiography with tissue Doppler measurements was used to assess regional myocardial function in patients with ischemic CHF. 31P magnetic resonance spectroscopy was used to assess the effect of perhexiline on skeletal muscle energetics in patients with nonischemic CHF. Treatment with perhexiline led to significant improvements in VO2max (16.1+/-0.6 to 18.8+/-1.1 mL . kg(-1) . min(-1); P<0.001), quality of life (Minnesota score reduction from 45+/-5 to 34+/-5; P=0.04), and left ventricular ejection fraction (24+/-1% to 34+/-2%; P<0.001). Perhexiline treatment also increased resting and peak dobutamine stress regional myocardial function (by 15% and 24%, respectively) and normalized skeletal muscle phosphocreatine recovery after exercise. There were no adverse effects during the treatment period.<h4>Conclusions</h4>In patients with CHF, metabolic modulation with perhexiline improved VO2max, left ventricular ejection fraction, symptoms, resting and peak stress myocardial function, and skeletal muscle energetics. Perhexiline may therefore represent a novel treatment for CHF with a good safety profile, provided that the dosage is adjusted according to plasma levels.
dc.description.statementofresponsibilityLeong Lee, Ross Campbell, Michaela Scheuermann-Freestone, Rachel Taylor, Prasad Gunaruwan, Lynne Williams, Houman Ashrafian, John Horowitz, Alan G. Fraser, Kieran Clarke, and Michael Frenneaux
dc.identifier.citationCirculation, 2005; 112(21):3280-3288
dc.identifier.doi10.1161/CIRCULATIONAHA.105.551457
dc.identifier.issn0009-7322
dc.identifier.issn1524-4539
dc.identifier.orcidHorowitz, J. [0000-0001-6883-0703]
dc.identifier.urihttp://hdl.handle.net/2440/17528
dc.language.isoen
dc.publisherLippincott Williams & Wilkins
dc.source.urihttps://doi.org/10.1161/circulationaha.105.551457
dc.subjectHeart failure
dc.subjectmetabolism
dc.subjectexercise
dc.subjectfatty acids
dc.subjectglucose
dc.titleMetabolic modulation with perhexiline in chronic heart failure - a randomized, controlled trial of short-term use of a novel treatment
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Medicine publications